Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Switching Strategy in the Management of Patients with Pulmonary Arterial Hypertension. The REPLACE Study Results

https://doi.org/10.20996/1819-6446-2020-11-11

Full Text:

Abstract

The article is devoted to topical issues of management of patients with pulmonary arterial hypertension and strategies for switching to riociguat therapy in patients with insufficient clinical response against the background of phosphodiesterase type 5 (PDE-5) inhibitors. The role of the NO metabolic pathway in the development of pulmonary arterial hypertension (PAH) was shown. From the standpoint of pathogenesis, the importance of the effect of medication on this pathway through soluble guanylate cyclase (sGC) has been assessed. The effects of the drug riociguat, the only member of the sGC stimulant class approved for the treatment of PAH, are associated with a dual mechanism of action: riociguat sensitizes the sGC enzyme to endogenous NO by stabilizing the NO-sGC bond, and also directly stimulates the latter through another site of the bond, regardless of NO. The favorable efficacy and safety profile of riociguat has been demonstrated in the PATENT-1,2 studies. During therapy, patients showed an improvement in exercise tolerance, functional class, and a number of other indicators. Studies that indicate the feasibility of using a change in therapy in clinical practice are reviewed. In particular, the article provides a detailed analysis of the REPLACE study. It demonstrated a significantly greater likelihood of achieving clinical improvement and a significant decrease in the rate of development of clinical deterioration when switching patients with PAH from PDE-5 inhibitors to riociguat. This therapy was well tolerated and can be considered as a strategy for managing patients at intermediate risk with insufficient patient response to PDE-5 inhibitors. In conclusion, the need to plan the need for specific therapy for pulmonary arterial hypertension in the region is noted in order to rapidly escalate therapy to achieve a low risk of mortality in these patients.

About the Author

E. V. Filippov
Ryazan State Medical University n.a. Academician I.P. Pavlov
Russian Federation

Evgeny V. Filippov - MD, PhD, Professor, Head of the Chair of Polyclinic Therapy and Preventive Medicine, Ryazan State Medical University n.a. Academician I.P. Pavlov.
Vysokovoltnaya ul. 9, Ryazan, 390026.



References

1. Galie N., Humbert M., Vachiery J.L., et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119. DOI:10.1093/eurheartj/ehv317.

2. Lam C.S., Borlaug B.A., Kane G.C., et al. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation. 2009;119(20):2663-70. DOI:10.1161/CIRCULATIONAHA.108.838698.

3. Humbert M., Guignabert C., Bonnet S., et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019;53:1801887. DOI:10.1183/13993003.01887-2018.

4. Chazova I.E., Martynyuk T.V. Pulmonary Hypertension. Moscow: Practice; 2015 (In Russ.)

5. Moncada S., Palmer R.M., Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43(2):109-42. PMID: 1852778.

6. Lambert L.E., French J.F., Whitten J.P., et al. Characterization of cell selectivity of two novel inhibitors of nitric oxide synthesis. Eur J Pharmacol. 1992;216(1):131-4. DOI:10.1016/0014-2999(92)90221-o.

7. Hogman M., Frostell C., Arnberg H., et al. Bleeding time prolongation and NO inhalation. Lancet. 1993;341(8861):1664-5. DOI:10.1016/0140-6736(93)90802-n.

8. Hemnes A.R., Champion H.C. Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension. Expert Rev Cardiovasc Ther. 2006;4(3):293-300. DOI:10.1586/14779072.4.3.293.

9. Chazova I.E., Martynyuk T.V., Valieva Z.S., et al. Eurasian Association of Cardiology. Clinical practice guidelines for the diagnosis and treatment of pulmonary hypertension (2019) [cited by Sep 09, 2020]. Available at: http://cardio-eur.asia/media/files/clinical_recommendations/Klinicheskiye_rekomendatsii_Yevraziyskoy_assotsiatsii_kardiologov_po_diagnostike_i_lecheniyu_legochnoy_gipertenzii_2019.pdf (In Russ.)

10. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148-57. DOI:10.1056/NEJMoa050010.

11. Michelakis E.D., Tymchak W., Noga M., et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation. 2003;108(17):2066-9. DOI:10.1161/01.CIR.0000099502.17776.C2.

12. Stasch J.P., Pacher P., Evgenov O.V. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011;123(20):2263-73. DOI:10.1161/CIRCULATIONAHA.110.981738.

13. Guha M. First-in-class guanylate cyclase stimulator approved for PAH. Nat Biotechnol. 2013;31:1064. DOI:10.1038/nbt1213-1064b.

14. Evgenov O.V., Pacher P., Schmidt P.M., et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006 Sep;5(9):755-68. DOI:10.1038/nrd2038.

15. Frey R., Muck W., Unger S., et al. Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. J Clin Pharmacol. 2008;48(8):926-34. DOI:10.1177/0091270008319793.

16. Grimminger F., Weimann G., Frey R., et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J. 2009;33(4):785-92. DOI:10.1183/09031936.00039808.

17. Ghofrani H.A., Galie N., Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330-40. DOI:10.1056/NEJMoa1209655.

18. Rubin L.J., Galie N., Grimminger F., et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J. 2015;45(5):1303-13. DOI:10.1183/09031936.00090614.

19. Lang M., Kojonazarov B., Tian X., et al. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS One. 2012;7(8):e43433. DOI:10.1371/journal.pone.0043433.

20. Taran, I.N., Belevskaya, A.A., Saidova, M.A., et al. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular-Pulmonary Arterial Coupling. Lung. 2018;196(6):745-53. DOI:10.1007/s00408-018-0160-4.

21. Hoeper M.M., Simonneau G., Corris P.A., et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J. 2017;50(3):1602425. DOI:10.1183/13993003.02425-2016.

22. Gall H., Vachiery J.L., Tanabe N., et al. Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH. Lung. 2018;196(3):305-12. DOI:10.1007/s00408-018-0100-3.

23. Hoeper M.M., Ghofrani H.A., Al-Hiti H., et al. Switching from phosphodiesterase type 5 inhibitors to riociguat in patients with pulmonary arterial hypertension: The REPLACE study. E-POSTER (Nr 3802) presented on the ERS 2020 International Conference Virtual Platform [cited by 09.09.2020] Available from: https://ers.conference2web.com/#!resources/late-breaking-abstract-switching-from-pde5i-to-riociguat-in-patients-with-pah-the-replace-study-158fd49b-b44a-495f-929d-3d5212141655.

24. Decree of the Government of the Russian Federation of 04/26/2012 N 403 (ed. Of 09/04/2012) “On the procedure for maintaining the Federal Register of persons suffering from life-threatening and chronic progressive rare (orphan) diseases leading to a reduction in the life expectancy of citizens or their disability, and its regional segment” [Cited 10.10.2020]. Available at: https://base.garant.ru/70168888/ (In Russ.)

25. Resolution of the Government of the Russian Federation of July 30, 1994 N 890 “On state support for the development of the medical industry and improving the provision of the population and healthcare institutions with medicines and medical products” [cited 10.10.2020]. Available at: https://base.garant.ru/101268/ (In Russ.)

26. Order of the Government of the Russian Federation of October 12, 2019 N 2406-r On approval of the list of vital and essential medicines for medical use for 2020, the list of medicines for medical use, including medicines for medical use, prescribed by decision of medical commissions medical organizations, a list of drugs intended to provide people with hemophilia, cystic fibrosis, pituitary dwarfism, Gaucher disease, as well as the minimum range of drugs required for the provision of medical care (with amendments and additions) [cited 10.10.2020]. Available at: https://base.garant.ru/72861778/#friends (In Russ.)

27. Galie N., Channick R.N., Frantz R.P., et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889. DOI:10.1183/13993003.01889-2018.


For citation:


Filippov E.V. Switching Strategy in the Management of Patients with Pulmonary Arterial Hypertension. The REPLACE Study Results. Rational Pharmacotherapy in Cardiology. 2020;16(6):1009-1016. (In Russ.) https://doi.org/10.20996/1819-6446-2020-11-11

Views: 319


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)